We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Organon and Co

Organon and Co (OGN)

At close: June 21 4:00PM
( 0.00% )
After Hours: 4:41PM


StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.5016.6020.300.0018.450.000.00 %00-
5.0015.4017.900.0016.650.000.00 %00-
7.5011.6015.400.0013.500.000.00 %00- %00-
12.500. %00- %00-
17.503.205.303. %41311:54:38 %00-
22.500. %1693315:54:56 %02,038- %01-

Professional-Grade Tools, for Individual Investors.


StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.750. %00- %00-
7.500.000.750. %00- %00-
12.500. %00- %0113-
17.500. %00- %00-
22.500. %00- %00-
30.008.7010.200.009.450.000.00 %00-

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
EPOWSunrise New Energy Company Ltd
$ 1.01
NXLNexalin Technologies Inc
$ 2.22
ALLRAllarity Therapeutics Inc
$ 0.5599
AGFYAgrify Corporation
$ 0.3001
WLDSWearable Devices Ltd
$ 0.545
OMICSingular Genomics Systems Inc
$ 0.30
NMHINatures Miracle Holding Inc
$ 0.5298
AREBAmerican Rebel Holdings Inc
$ 0.6617
WRNTWarrantee Inc
$ 0.291
IPDNProfessional Diversity Network Inc
$ 0.4899
NVDANVIDIA Corporation
$ 127.02
COMMCommScope Holding Company Inc
$ 1.27
AAPLApple Inc
$ 207.72
GOOGAlphabet Inc
$ 181.01
GOOGLAlphabet Inc
$ 179.80

OGN Discussion

View Posts
Monksdream Monksdream 5 months ago
OGN not so hot from a chart standpoint
LordDarley LordDarley 3 years ago
Looks good.
There is also a very nice analysis on seeking Alpha. Shows pros and cons, and is professional quality IMHO. Much more detail than the Barron's article.
DewDiligence DewDiligence 3 years ago
Barron’s bullish on OGN: Organon (OGN), which Merck (MRK) jettisoned this past week, could be another winner. This is a classic spinoff situation. Organon is a group of noncore Merck businesses—off-patent drugs sold mainly overseas, biosimilars, and a women’s health business—that may fare better as an independent company.
“You easily can see how this business could have been lost inside of Merck and been undermanaged relative to the rest of the portfolio,” says James Hounsell, a senior research analyst at Smead Capital Management, a Merck shareholder. “That’s when the magic happens with spinoffs.”

The shares trade around $34, giving the company a market value of $8.6 billion, plus about $9 billion of net debt. Merck shareholders received one Organon share for every 10 of Merck. Organon trades for just six times 2020 profits of $5.90 a share. Similar earnings are expected this year.

Organon isn’t as cheap when valued against projected 2021 earnings before interest, taxes, depreciation, and amortization, or Ebitda, of $2.3 billion, based on its enterprise value of equity value plus net debt. Then, it trades around eight times, in line with mature drug companies.

At a May investor day, Merck projected $6.1 billion to $6.4 billion of 2021 revenue for Organon and annual sales increases in the low- to mid-single digits. The dividend hasn’t been set yet, but based on Organon’s financial guidance, it could be about 3%.

Major drivers for the company are expected to be an implantable women’s contraceptive called Nexplanon and biosimilars, which are generic versions of bioengineered drugs.

“This is a stable, predictable business with low- to mid-single digit growth organically,” Organon CEO Kevin Ali tells Barron’s. He is bullish on the growth outlook for the women’s health business, now about 25% of revenue, plus the opportunity for potential acquisitions.

Given its low price/earnings ratio, Organon has good appreciation potential if it can deliver on its financial goals.
DewDiligence DewDiligence 3 years ago
OGN spin-off from MRK begins trading today:

Your Recent History

Delayed Upgrade Clock